Capital CS Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Capital CS Group’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,457	Closed	-$337K	–	66
2025 Q4	$337K	Buy	+14,457	New	+$322K	0.52%	35

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital CS Group's CPRX Position: Q1 2026 in Review

Capital CS Group sold out of Catalyst Pharmaceutical (CPRX) in Q1 2026, closing a stake of 14,457 shares — an estimated $337K sold.

Capital CS Group first reported a position in CPRX in Q4 2025 and held it in 1 quarter. The position peaked at $337K in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Capital CS Group reported no remaining Catalyst Pharmaceutical position as of Q1 2026 after selling out during the quarter.
Capital CS Group sold 14,457 Catalyst Pharmaceutical shares in Q1 2026, an estimated $337K.
Capital CS Group first reported a position in Catalyst Pharmaceutical in Q4 2025 and held it in 1 quarter.
Capital CS Group's Catalyst Pharmaceutical position peaked at $337K in Q4 2025.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Capital CS Group's 13F filing for Q1 2026, filed 13 May 2026.